Please login to order a test.
Vedolizumab and Anti-Vedolizumab Antibody
- Anti-integrin drug
- Biological monitoring
- Immunogenicity testing
Provides serum concentrations of vedolizumab and anti-vedolizumab antibodies in order to optimize treatment and facilitate clinical decision-making.
Drug half-life should be taken into consideration when interpreting concentrations measured in non-trough collections.
Electrochemiluminescence Immunoassay (ECLIA)
In the absence of anti-vedolizumab antibodies, the vedolizumab drug level reflects the total vedolizumab concentration. In the presence of anti-vedolizumab antibodies, the vedolizumab concentration reflects the antibody-unbound fraction of vedolizumab.
The presence of vedolizumab drug, even at concentrations well above target treatment levels , does not interfere with anti-vedolizumab antibody measurement. All positive anti-vedolizumab antibody results are verified by a confirmatory test.
Serum or plasma
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum/plasma in a plastic transport tube. To avoid delays in turnaround time when requesting multiple test on frozen samples, please submit separate frozen specimens for each test requested.
Causes for Rejection
Gross hemolysis; gross lipemia
This assay is currently not available in New York.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|504567||Vedolizumab and Anti-Vedo Ab||504568||Vedolizumab||ug/mL||86898-4|
|504567||Vedolizumab and Anti-Vedo Ab||504569||Anti-Vedolizumab Antibody||ng/mL||86899-2|
|504567||Vedolizumab and Anti-Vedo Ab||000000||Esoterix Informed Consent Req||N/A|